Tirzepatide, an injectable drug developed by Lilly with the trade name Mounjaro, is seen as a promising treatment against obesity after obtaining convincing results that allow patients with type 2 diabetes to lose weight efficiently and sustainably with a weekly injection.
A single weekly injection could be as effective for weight loss as bariatric surgery in people with obesity. The drug would benefit patients suffering from insidious type 2 diabetes, in whom losing weight is a therapeutic measure.
